(Press-News.org) Journal: Nature Cardiovascular Research – June 13 Online Issue
Author: Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai
Title: Secondary analysis of the EMPACT-MI Trial Reveals Cardiovascular-Kidney Efficacy and Safety of Empagliflozin After Acute Myocardial Infarction
Bottom line of study: SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients after recent heart attack due to concerns about harming kidney function in potentially unstable patients.
This secondary analysis of the EMPACT-MI trial demonstrates the SGLT2 inhibitor empagliflozin preserved kidney function and was safe to initiate in heart attack patients. Researchers found that after heart attack patients were on the drug for two years, their kidney function was stable and unharmed, while patients on placebo had significant worsening of their kidney function.
Even in heart attack patients with poor kidney function, researchers found SGLT2 inhibitors reduced heart failure complications. This is important considering that drugs that are beneficial in patients without kidney disease sometimes don’t work for patients with kidney disease. This was not the case with empagliflozin.
Why this study is important: Many heart attack patients who could benefit from SGLT2 inhibitors do not currently receive these drugs because many doctors fear they could damage kidney function. Results from this study, the largest trial to date of an SGLT2 inhibitor in patients with heart attacks, may change this.
How the research was conducted: Researchers randomized 6,522 patients hospitalized with a heart attack to either an SGLT2 inhibitor or placebo, on average five days after the heart attack. Patients were followed for an average of a year and a half.
Study results: Empagliflozin reduced total hospitalizations for heart failure by 33 percent (2.4 events per 100 person-years in the empagliflozin group and 3.6 events per 100 person-years in the placebo group) with consistent effects according to kidney function. The difference in eGFR change (a measure of kidney function) between empagliflozin and placebo was 4.1 ml/min/1.73 m2), indicating significant worsening of kidney function in the placebo group after two years.
What the study means for clinicians and patients: Clinicians should be vigilant when it comes to treating patients who might benefit from SGLT2 inhibitors and not withhold therapy due to a recent heart attack or because of kidney disease, since these study results show these drugs will not impact kidney function.
Quotes: “SGLT2 inhibitors are underused in clinical practice. These data provide reassurance of the safety of using this class of drugs when indicated—even in patients after a recent heart attack and if the kidney function is impaired,” says lead investigator Dr. Bhatt.
About the EMPACT-MI trial: EMPACT-MI trial (EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction, NCT04509674) is a multicenter, randomized, parallel-group, double-blind, placebo-controlled superiority trial investigating the effect of empagliflozin on all-cause mortality and hospitalization due to heart failure in adults who have had a heart attack. Participants had no history of chronic heart failure and were eligible regardless of type 2 diabetes and chronic kidney disease status. EMPACT-MI included more than 6,500 adults from 22 countries. Study participants were randomized to receive either empagliflozin 10 mg or placebo, once daily, both on top of standard of care within 14 days of hospital admission for heart attack. The EMPACT-MI clinical trial was conducted, analyzed, and reported by Boehringer Ingelheim in partnership with the Duke Clinical Research Institute (DCRI), with Boehringer Ingelheim and Lilly providing funding. The primary results of the EMPACT-MI trial had been presented at the Annual Scientific Session of American College of Cardiology, Apr 06-08, 2024, Atlanta and published in the New England Journal of Medicine.
Funding: Boehringer Ingelheim funded the trial and these analyses
Mount Sinai Is a World Leader in Cardiology and Heart Surgery
Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital ranks No. 4 nationally for cardiology, heart, and vascular surgery, according to U.S. News & World Report®. It also ranks No. 1 in New York and No. 6 globally according to Newsweek’s “The World’s Best Specialized Hospitals.”
It is part of Mount Sinai Health System, which is New York City's largest academic medical system, encompassing seven hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 9,000 primary and specialty care physicians; 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 45 multidisciplinary research, educational, and clinical institutes. Hospitals within the Health System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report's® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
END
SGLT2 inhibitor empagliflozin treatment stabilizes kidney function in patients who have had a heart attack
2025-06-13
ELSE PRESS RELEASES FROM THIS DATE:
City of Hope developed a foundational map of tumor cells for personalized brain cancer treatments
2025-06-13
LOS ANGELES — City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, co-led the first study to demonstrate that characterizing genetic material near chromosomes forecasts how mutated, cancer-causing genes reengineer DNA and alter the tumor microenvironment. The leading-edge brain cancer research provides foundational knowledge that one day will improve the practice of precision medicine and allow oncologists to deliver more personalized therapies to cancer patients.
Tiny DNA molecules ...
Pangolins in Africa hunted for food rather than illicit scales trade – with meat ranked as ‘tastiest’
2025-06-13
Study suggests that appetite for bushmeat – rather than black market for scales to use in traditional Chinese medicine – may be driving West Africa’s illegal hunting of one of the world’s most threatened mammals.
Interviews with hundreds of hunters show pangolins overwhelmingly caught for food, with majority of scales thrown away. Survey work shows pangolin is considered the most palatable meat in the region.
The vast majority of pangolin hunting in African ...
How solvents shape precision drug delivery
2025-06-13
Even the best products won’t meet expectations if they are packed poorly — packaging matters. The same goes for drug delivery.
Osaka Metropolitan University researchers have uncovered the critical role played by solvents in how effectively drugs can be loaded into metal–organic frameworks (MOFs), a promising class of drug carriers. Their findings shed light on a previously overlooked part of the loading process, with the potential to boost the efficiency of how medications are delivered inside the body.
To treat diseases effectively, it’s not just the medicine that counts — but also how that medicine is delivered into our ...
Swarm intelligence directs longhorn crazy ants to clear the road ahead for sisters carrying bulky food
2025-06-13
Among the tens of thousands of ant species, incredible ‘intelligent’ behaviors like crop culture, animal husbandry, surgery, ‘piracy’, social distancing, and complex architecture have evolved. Yet at first sight, the brain of an ant seems hardly capable of such feats: it is about the size of a poppy seed, with only 0.25m to 1m neurons, compared to 86bn for humans. Now, researchers from Israel and Switzerland have shown how ‘swarm intelligence’ resembling advance planning can nevertheless emerge from the concerted operation of many of ...
Vaccinated patients hospitalized with COVID-linked acute kidney injury less likely to need dialysis, and more likely to survive, after discharge
2025-06-13
Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests. The study found vaccinated patients were less likely to stay on dialysis after discharge, and more likely to survive, than unvaccinated patients.
Acute kidney injury, or AKI, is common among people infected with COVID-19, with rates running as high at 46%. It can lead to a mild decrease in kidney function or, if severe enough, to dialysis. The long-term renal and survival outcomes of these patients, however, has not been ...
What’s driving the rise of NLM wines?
2025-06-13
New research from Adelaide Business School at the University of Adelaide provides a framework for understanding the growing consumer interest in no, low and mid (NLM) alcohol wines.
Dr Hannah Ford’s comprehensive scoping review, published in Journal of Marketing Management , suggests that consumer adoption of NLM wines is influenced by a range of factors, while wine businesses themselves play a pivotal role.
“The global wine industry is evolving rapidly in response to growing health-conscious and moderation-driven drinking trends,” Dr Ford explains. “The review proposes that appeal to NLM wines is influenced ...
Koalas set to benefit from new genetic screening tool
2025-06-13
A University of Queensland-led project has developed a tool to standardise genetic testing of koala populations, providing a significant boost to conservation and recovery efforts.
Dr Lyndal Hulse from UQ’s School of the Environment said the standardised koala genetic marker panel provides a consistent method for researchers nationwide to capture and share koala genetic variation, enabling improved collaboration and data integration across studies.
“Koalas in the wild are under increasing pressure ...
Scientists discover the ‘ticking’ mechanism driving nature’s simplest circadian clock
2025-06-13
Aichi, Japan--Researchers from the Institute for Molecular Science (IMS)/SOKENDAI and Kyushu University have uncovered the molecular mechanism that drives the "ticking" of the circadian clock in cyanobacteria. Their study reveals how a clock protein called KaiC controls chemical reactions with remarkable precision, acting like the hand of a clock that waits, then moves at just the right moment. The findings were published in PNAS Nexus on April 28, 2025.
To adapt to Earth's daily rotation, most living organisms, from simple, single-celled bacteria to complex, multicellular ...
Potential anti-breast cancer drug identified
2025-06-13
A surgeon can excise breast cancer from the body, but even the most skilled scalpel may not be able to remove every cell — especially when the cells have spread from the original disease site elsewhere in the body. This proliferation and migration of breast cancer cells involves many still unknown molecular means, but researchers at Hiroshima University have elucidated at least one mechanism. With the discovery, they may have also uncovered how short chains of protein building blocks could serve as a novel anticancer drug.
The team published their findings on April 9 in the British Journal of Pharmacology. ...
Major review finds 34% reduction in suicide risk following electroconvulsive therapy in patients with severe depression
2025-06-12
A newly published analysis reveals that individuals with severe depression who received electroconvulsive therapy (ECT) were 34% less likely to die by suicide compared to those treated with standard alternatives such as anti-depressant medication. This comprehensive meta-analysis (an analysis pooling and synthesizing previous studies), building on prior research and incorporating the most up-to-date evidence — is the first of its kind to demonstrate such a significant reduction in suicide risk linked to ECT. The findings also show that patients receiving ECT had 30% fewer deaths from any cause, suggesting broader health benefits beyond mental health.
Researchers ...